var data={"title":"Verteporfin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Verteporfin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7149?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=verteporfin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Verteporfin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13164018\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Visudyne</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233956\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Visudyne</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233974\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Ophthalmic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233959\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Therapy is a two-step process; first the infusion of verteporfin, then the activation of verteporfin with a nonthermal diode laser (for light administration details, see Administration).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Subfoveal choroidal neovascularization: </b>IV: 6 mg/m<sup>2</sup> body surface area; may repeat at 3-month intervals (if evidence of choroidal neovascular leakage)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note: </b> Treatment in more than one eye: Patients who have eligible lesions in both eyes should be evaluated and treatment should first be done to the more aggressive lesion. Following safe and acceptable treatment, the second eye can be treated one week later. Patients who have had previous verteporfin therapy, with an acceptable safety profile, may then have both eyes treated concurrently (~3 months after the initial treatment). Treat the more aggressive lesion followed immediately with the second eye. The light treatment to the second eye should begin no later than 20 minutes from the start of the infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233960\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Patients &ge;75 years were less likely to benefit from therapy in clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13913733\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however it is unlikely that patients with renal impairment will be affected since elimination is predominantly via the feces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233961\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, half-life is increased by 20% with mild hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate-to-severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233939\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visudyne: 15 mg (1 ea) [contains egg phosphatidylglycerol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233924\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233941\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse at 3 mL/minute (over 10 minutes) using a syringe pump and an in-line filter (a standard 1.2 micron filter was used in studies). A free-flowing IV line should be established prior to starting infusion. Use of the largest arm vein, especially in elderly patients, is suggested; avoid small veins in the back of the hand. Avoid extravasation; if extravasation occurs, protect the infusion site from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Extravasation management: </b>Stop infusion. To decrease the chance of a severe burn, protect the area of extravasation from direct light until swelling and discoloration have faded. Apply cold compresses to the injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avoid contact with skin and eyes during preparation and administration; if contact occurs, protect contact area from bright light.  Any spill should be wiped with a damp cloth (the use of rubber gloves is recommended); dispose of all materials properly.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Light administration: Following intravenous infusion, verteporfin must be light activated using a nonthermal diode laser. The system must provide a stable power output at a wavelength of 689 &plusmn; 3 nm. Approved laser systems are listed in manufacturer's package insert. Light delivery should begin 15 minutes following the start of the 10-minute infusion. The light dose is 50 J/cm<sup>2</sup> of neovascular lesion administered over 83 seconds at an intensity of 600 mW/cm<sup>2</sup>. Detailed instructions for determining lesion size, treatment spot size, and light administration may be found in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233940\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subfoveal choroidal neovascularization: </b>Treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Limitations of use: There is insufficient evidence to indicate verteporfin for the treatment of predominantly occult subfoveal choroidal neovascularization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233930\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (including extravasation, inflammation at injection site, local discoloration, local edema, local hemorrhage, pain at injection site, rash at injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, decreased visual acuity, photopsia, visual field defect (including scotoma)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, hypertension, peripheral vascular disease, varicose veins</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Disturbed sleep, hypoesthesia, myasthenia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Eczema, skin photosensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Albuminuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Prostatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, gastrointestinal carcinoma, leukocytosis, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain (primarily during infusion), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal lacrimation, blepharitis (at treatment site), cataract (at treatment site), conjunctivitis (at treatment site), conjunctival injection (at treatment site), diplopia, eye pruritus (at treatment site), severe vision loss (1% to 5%; at treatment site, with or without subretinal/retinal or vitreous hemorrhage; decrease in 4 lines or more within 7 days of treatment), xerophthalmia (at treatment site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, flu-like symptoms, pharyngitis, pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, vasodepressor syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (during infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Retinal detachment (nonrhegmatogenous), retinal ischemia (retinal or choroidal vessel nonperfusion), retinal pigment epithelium tear</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233944\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to verteporfin or any component of the formulation; porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Severe hepatic impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233928\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: May cause severe pain, swelling, inflammation, or discoloration at the injection site if the extravasated area is exposed to light. Standard precautions should be taken to avoid extravasation (eg, free-flowing IV line, use of largest arm vein [antecubital, if possible]; avoid using small veins on the back of the hand). If extravasation occurs, stop the infusion immediately and protect area from direct light until swelling and discoloration have faded; use cold compresses and oral pain medications, if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Chest pain, dyspnea, flushing, syncope/vasovagal and hypersensitivity reactions have occurred rarely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: May cause visual disturbances such as abnormal vision, decreased vision, or visual field defects; these effects may interfere with the ability to drive or use machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid exposing skin or eyes to direct sunlight or bright indoor light for 5 days following treatment (ambient indoor light is acceptable and encouraged); in case of emergency surgery within 48 hours of treatment, protect as much of the internal tissue as possible from intense light. Prolonged exposure to light from light-emitting medical devices (eg, pulse oximeter) should be avoided for 5 days after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &ge;75 years are less likely to benefit from therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not re-treat patients who experience a decrease of vision &ge;4 lines within 1 week of treatment unless vision recovers and the potential benefits and risks are carefully considered. Patients with dark irides, occult lesions, or &lt;50% classic choroidal neovascularization are less likely to benefit from therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concurrent administration in both eyes: Use in more than one eye has not been studied; however, it is recommended that in patients requiring treatment in both eyes, initial treatment should be applied to the more aggressive lesion first, and after safe and effective treatment to the initial eye, the second eye may be treated 1 week later. After ~3 months and an acceptable safety profile with initial treatment, both eyes may be treated concurrently. Treat the more aggressive lesion first, followed immediately with the second eye. The light treatment to the second eye should begin no later than 20 minutes from the start of the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: Safety and efficacy have not been established of use for longer than 2 years.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300216\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233932\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10032&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Photosensitizing Agents: May enhance the photosensitizing effect of Verteporfin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233953\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may decrease efficacy of verteporfin. Management: Avoid ethanol during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233934\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233946\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F518319\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Verteporfin and its metabolite are excreted in breast milk. Milk concentrations were up to 66% of plasma levels in 1 woman following infusion; the metabolite was still detected 48 hours later. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that nursing be discontinued or treatment be postponed, taking into account the importance of treatment to the mother. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233937\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor intravenous site during infusion, to avoid extravasation; fluorescein angiography every 3 months to monitor choroidal neovascular leakage (if detected, repeat therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233927\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Following intravenous administration, verteporfin is transported by lipoproteins to the neovascular endothelium in the affected eye(s), including choroidal neovasculature and the retina. Verteporfin then needs to be activated by nonthermal red light, which results in local damage to the endothelium, leading to temporary choroidal vessel occlusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233943\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and by plasma esterases to diacid metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 5 to 6 hours, biexponential </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (predominantly); urine (&lt;0.01%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324086\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Visudyne Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,963.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233947\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Visudine (GR);</li>\n      <li>Visudyne (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GB, HK, HN, HR, HU, ID, IE, IL, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Visudyne (verteporfin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visudyne (verteporfin) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; January 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10032 Version 95.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13164018\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233956\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F233974\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F233959\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F233960\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13913733\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F233961\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233939\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F233924\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F233941\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F233940\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233930\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233944\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233928\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300216\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233932\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F233953\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233934\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233946\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F518319\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F233937\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233927\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F233943\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324086\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233947\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10032|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=verteporfin-patient-drug-information\" class=\"drug drug_patient\">Verteporfin: Patient drug information</a></li></ul></div></div>","javascript":null}